Centre for Kidney Disease Research, The University of Queensland, Brisbane, Australia.
Translational Research Institute, Brisbane, Australia.
PLoS One. 2019 Jan 17;14(1):e0210246. doi: 10.1371/journal.pone.0210246. eCollection 2019.
Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney cancer, which is difficult to treat and lacks a reliable prognostic marker. A previous study showed that the endoplasmic reticulum stress marker, glucose-regulated-protein-78 (GRP78), is a potential prognostic marker for ccRCC. The present study aimed to: (1) examine whether GRP78 was upregulated in ccRCC compared with matched non-neoplastic renal tissue; and (2) investigate whether GRP78 expression in ccRCC tissue or perinephric adipose tissue has any association with ccRCC aggressiveness.
A retrospective cross-sectional study of 267 patients who underwent nephrectomy for renal tumors between June 2013 and October 2017 was conducted at Princess Alexandra Hospital, Brisbane, Australia. Software-assisted quantification of average grey value of staining intensity (staining intensity method) and proportion of positive pixels (positive pixel method) was applied to measure expression of GRP78 in archived specimens of renal tumor tissues (n = 114), adjacent non-neoplastic renal tissues (n = 68), and perinephric adipose tissues (n = 60) in participants diagnosed with ccRCC.
GRP78 was not upregulated in renal tumor tissue compared with paired normal renal tissue. In tumor tissue, GRP78 expression did not show any association with ccRCC aggressiveness using either quantification method. In adipose tissue, downregulation of GRP78 demonstrated poor correlation with increased probability of metastasis, with one unit increase in average grey value of GRP78 staining weakly correlating with a 17% increase in the odds ratio of metastasis (95% confidence interval: 0.99 to 1.38, p = 0.07).
GRP78 is not valuable as a risk stratification marker for ccRCC.
透明细胞肾细胞癌(ccRCC)是最常见的肾癌亚型,其治疗困难且缺乏可靠的预后标志物。先前的研究表明,内质网应激标志物葡萄糖调节蛋白 78(GRP78)是 ccRCC 的潜在预后标志物。本研究旨在:(1)检测与匹配的非肿瘤性肾组织相比,ccRCC 中 GRP78 是否上调;(2)研究 ccRCC 组织或肾周脂肪组织中 GRP78 的表达与 ccRCC 侵袭性是否存在任何关联。
在澳大利亚布里斯班的亚历山德拉公主医院对 2013 年 6 月至 2017 年 10 月期间接受肾肿瘤切除术的 267 例患者进行了回顾性横断面研究。应用软件辅助对染色强度的平均灰度值(染色强度法)和阳性像素比例(阳性像素法)进行定量,以测量存档的肾肿瘤组织标本(n=114)、配对的非肿瘤性肾组织(n=68)和肾周脂肪组织(n=60)中 GRP78 的表达情况,这些患者均被诊断为 ccRCC。
与配对的正常肾组织相比,肿瘤组织中 GRP78 并未上调。在肿瘤组织中,无论采用哪种定量方法,GRP78 的表达与 ccRCC 的侵袭性均无关联。在脂肪组织中,GRP78 的下调与转移概率的增加显示出较差的相关性,GRP78 染色的平均灰度值增加一个单位,转移的优势比(OR)增加 17%(95%置信区间:0.99 至 1.38,p=0.07)。
GRP78 不能作为 ccRCC 的风险分层标志物。